Pfizer to Pay Record $2.3B Settlement
September 3, 2009
Pfizer will pay a record fine to settle allegations that it improperly marketed its drugs.
September 3, 2009
Pfizer will pay a record fine to settle allegations that it improperly marketed its drugs.
A Failure to Communicate
August 1, 2009 by Gretchen Michals
Boards and shareholders look for better ways to communicate as some investors believe corporate directors are giving them the silent treatment.
August 1, 2009 by Gretchen Michals
Boards and shareholders look for better ways to communicate as some investors believe corporate directors are giving them the silent treatment.
CombinatoRx and Nueromed to Merge
July 1, 2009
Pharmaceutical companies CombinatoRx and Nueromed Pharmaceuticals announced a merger today, with Combinato to acquire its industry peer in an all-stock deal.
July 1, 2009
Pharmaceutical companies CombinatoRx and Nueromed Pharmaceuticals announced a merger today, with Combinato to acquire its industry peer in an all-stock deal.
Pfizer Offers Concessions for Wyeth Deal
June 29, 2009
Pfizer offered to divest some or all of its animal health business assets to ease EU regulatory concerns of its merger with the pharmaceutical company Wyeth. The European Commission, the 27-state antitrust regulator, has until July 20 to review the Pfizer’s $65 billion acquisition of Wyeth, according to Bloomberg.
June 29, 2009
Pfizer offered to divest some or all of its animal health business assets to ease EU regulatory concerns of its merger with the pharmaceutical company Wyeth. The European Commission, the 27-state antitrust regulator, has until July 20 to review the Pfizer’s $65 billion acquisition of Wyeth, according to Bloomberg.
Global M&A Down 33 Percent
March 27, 2009 by Joseph McCafferty
Global mergers and acquisitions fell by a third in the first quarter to $444 billion, as the economic crisis deterred deal making.
March 27, 2009 by Joseph McCafferty
Global mergers and acquisitions fell by a third in the first quarter to $444 billion, as the economic crisis deterred deal making.
Pharma Sees Increase in M&A Activity
March 12, 2009 by Joseph McCafferty
Adding to what has been a period heavy with merger activity within the pharmaceutical sector, biotech firm Gilead Sciences will pay $1.4 billion to acquire CV Therapeutics.
March 12, 2009 by Joseph McCafferty
Adding to what has been a period heavy with merger activity within the pharmaceutical sector, biotech firm Gilead Sciences will pay $1.4 billion to acquire CV Therapeutics.
Merck to Buy Out Rival Schering-Plough
March 9, 2009 by Joseph McCafferty
Pharmaceutical company Merck announced this morning its intentions to buy out rival Schering-Plough in a merger that will further consolidate the pharmaceuticals and health products industry.
March 9, 2009 by Joseph McCafferty
Pharmaceutical company Merck announced this morning its intentions to buy out rival Schering-Plough in a merger that will further consolidate the pharmaceuticals and health products industry.
Pfizer Will Disclose Doctor Payments
February 11, 2009
Pfizer said Monday that it will begin disclosing payments to health-care professionals for consulting, speaking engagements, and clinical trials.
February 11, 2009
Pfizer said Monday that it will begin disclosing payments to health-care professionals for consulting, speaking engagements, and clinical trials.
Execs at Davos Predict Rise in M&A
January 30, 2009 by Joseph McCafferty
Business leaders at the World Economic Forum see an increase in merger and acquisition activity as industries consolidate in response to the recession.
January 30, 2009 by Joseph McCafferty
Business leaders at the World Economic Forum see an increase in merger and acquisition activity as industries consolidate in response to the recession.
Pfizer to Pay $68B for Rival Wyeth
January 26, 2009 by Joseph McCafferty
Pharmaceuticals giant Pfizer announced today that it would spend $68 billion to acquire rival Wyeth in one of the largest pharmaceuticals buyouts on record.
January 26, 2009 by Joseph McCafferty
Pharmaceuticals giant Pfizer announced today that it would spend $68 billion to acquire rival Wyeth in one of the largest pharmaceuticals buyouts on record.
Pharma Awaits Court Ruling on Right to Sue
October 27, 2008 by Joseph McCafferty
In a closely watched case, the Supreme Court is expected to rule next week on a case that could determine a plaintiffs' right to sue.
October 27, 2008 by Joseph McCafferty
In a closely watched case, the Supreme Court is expected to rule next week on a case that could determine a plaintiffs' right to sue.
ImClone’s Sale Talks Continue
September 29, 2008 by Joseph McCafferty
ImClone Systems is expected to announce later today that it is continuing talks to sell itself to a major pharmaceutical concern for a price in the range of $6.1 billion. Activist investor Carl Icahn has been searching for a higher bid.
September 29, 2008 by Joseph McCafferty
ImClone Systems is expected to announce later today that it is continuing talks to sell itself to a major pharmaceutical concern for a price in the range of $6.1 billion. Activist investor Carl Icahn has been searching for a higher bid.
Pfizer Case Points to Unexpected Cost
March 10, 2008 by Joseph McCafferty
U.S. Chief Justice John Roberts' recusal last week from a case involving Pfizer in which he owns a small amount of stock may have contributed to a Supreme Court deadlock. That deadlock will allow lawsuits over Pfizer’s Rezulin diabetes drug. Roberts didn't take part in the case, and the court split 4-4, leaving Pfizer one vote short of stopping the suits.
March 10, 2008 by Joseph McCafferty
U.S. Chief Justice John Roberts' recusal last week from a case involving Pfizer in which he owns a small amount of stock may have contributed to a Supreme Court deadlock. That deadlock will allow lawsuits over Pfizer’s Rezulin diabetes drug. Roberts didn't take part in the case, and the court split 4-4, leaving Pfizer one vote short of stopping the suits.
Reg FD Is Quieting Directors
March 6, 2008 by Joseph McCafferty
Communications between directors and shareholders may be a bumpy road that is predominantly overshadowed by contentious debates like say-on-pay and proxy access, according to a developing policy report from Yale School of Management’s Millstein Center for Corporate Governance and Performance.
March 6, 2008 by Joseph McCafferty
Communications between directors and shareholders may be a bumpy road that is predominantly overshadowed by contentious debates like say-on-pay and proxy access, according to a developing policy report from Yale School of Management’s Millstein Center for Corporate Governance and Performance.